Business Wire

BOW Group Acquires Musart, Adding Innovative Art Marketplace to Its Offering

29.7.2021 16:15:00 EEST | Business Wire | Press release

Share

BOW Group today announced that it has successfully completed the acquisition of Musart.com, a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Musart)

“BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundamentally changing, disrupted with new players and media; we want to participate in that shift by helping consumers get access to art pieces and accessories, under different forms, at every price points.”

Since its inception in 2014, Musart has sold thousands of pieces of collectibles. Founded by French Art-Lover and Entrepreneur Vincent Gregoire, Musart’s mission is to make art accessible, giving anyone the opportunity to «own a piece of museum».

Partnerships with world-class museums, foundations and cultural organizations allow Musart to bring not only exclusive and authentic items, but also, to honor iconic artists such as Basquiat, Cattelan, Da Vinci, Dali, Haring, Hokusai, Kahlo, Klimt, Kusama, Magritte, Michelangelo, Miró, Modigliani, Mondrian, Picasso, Pollock, Van Gogh, Warhol. Licensed items, numbered and signed pieces include the world famous Kaws, Medicom Toy Be@rbricks and Kidrobot, as well as new promising talents. The selection spans multiple product categories: sculptures, home decor and office accessories, stationary, books, clothing, etc... with prices ranging from $20 to $20,000.

Customers receive not only an art piece but also a short biography of the corresponding artist for each purchase, proving Musart’s commitment to democratizing art and its educative vocation. Headquartered in Miami, Musart has first experienced a retail journey and embarked into a successful digital experience with its own website and 5-stars Central Seller page on Amazon, gathering today more than 1000 references and a highly active community of collectors.

By joining BOW Group, Musart will benefit from the group’s 360° platform, including a mature D2C digital ecosystem, multiple warehouse locations to serve consumers around the globe and its R&D center BOW Industries to handle its licensed and private label activities. One of the first objectives is to expand Musart’s sales activity outside the US, especially in Europe. While Musart will undoubtedly diversify BOW Group’s offering from a B2C standpoint, it will also meet the demand of B2B and Corporate customers with a whole new range of exciting gift objects.

Musart Founder Vincent Gregoire said: “I’m thrilled to join BOW Group with whom we share the same entrepreneurial mindset and consumer-driven approach. This integration marks a new chapter for Musart, one that will definitely help us reach our full potential at a global scale and embrace the new disruptive changes of our industry, such as NFTs. Leveraging BOW’s existing digital resources, ecommerce and supply chain infrastructure will take our business to another level, bringing innovative online experiences such as AR technology while continuing to make art accessible to anyone.”

Follow Musart

Instagram: https://www.instagram.com/musartboutique/

Facebook: https://www.facebook.com/musartboutique/

About BOW Group

BOW Group is a global player and multi-skilled platform operating worldwide with two consumer brands: Lexon, the design object editor, and MyKronoz, the IoT specialist - both powered by its own R&D and manufacturing center, BOW Industries. In addition, BOW Group owns the luxury concept-store chain Legacy.

Every year, BOW Group sells about 2 million pieces of products in 90 countries and across 9000 points of sales, thanks to its international recognition and network of leading designers celebrated with more than 200 Awards received, including 7 Red Dot Design Awards won by its two brands in 2021.

BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.

Since July 2015, BOW has opened up its capital to NextStage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Annabel Corlay
a.corlay@group-bow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye